[1]
Horn L,Mansfield AS,Szczęsna A,Havel L,Krzakowski M,Hochmair MJ,Huemer F,Losonczy G,Johnson ML,Nishio M,Reck M,Mok T,Lam S,Shames DS,Liu J,Ding B,Lopez-Chavez A,Kabbinavar F,Lin W,Sandler A,Liu SV, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. The New England journal of medicine. 2018 Dec 6;
[PubMed PMID: 30280641]
[2]
Balar AV,Galsky MD,Rosenberg JE,Powles T,Petrylak DP,Bellmunt J,Loriot Y,Necchi A,Hoffman-Censits J,Perez-Gracia JL,Dawson NA,van der Heijden MS,Dreicer R,Srinivas S,Retz MM,Joseph RW,Drakaki A,Vaishampayan UN,Sridhar SS,Quinn DI,Durán I,Shaffer DR,Eigl BJ,Grivas PD,Yu EY,Li S,Kadel EE 3rd,Boyd Z,Bourgon R,Hegde PS,Mariathasan S,Thåström A,Abidoye OO,Fine GD,Bajorin DF, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2017 Jan 7;
[PubMed PMID: 27939400]
[3]
Necchi A,Joseph RW,Loriot Y,Hoffman-Censits J,Perez-Gracia JL,Petrylak DP,Derleth CL,Tayama D,Zhu Q,Ding B,Kaiser C,Rosenberg JE, Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Dec 1;
[PubMed PMID: 28950298]
[4]
Herbst RS,Giaccone G,de Marinis F,Reinmuth N,Vergnenegre A,Barrios CH,Morise M,Felip E,Andric Z,Geater S,Özgüroğlu M,Zou W,Sandler A,Enquist I,Komatsubara K,Deng Y,Kuriki H,Wen X,McCleland M,Mocci S,Jassem J,Spigel DR, Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. The New England journal of medicine. 2020 Oct 1;
[PubMed PMID: 32997907]
[5]
Socinski MA,Jotte RM,Cappuzzo F,Orlandi F,Stroyakovskiy D,Nogami N,Rodríguez-Abreu D,Moro-Sibilot D,Thomas CA,Barlesi F,Finley G,Kelsch C,Lee A,Coleman S,Deng Y,Shen Y,Kowanetz M,Lopez-Chavez A,Sandler A,Reck M, Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. The New England journal of medicine. 2018 Jun 14;
[PubMed PMID: 29863955]
[6]
Schmid P,Rugo HS,Adams S,Schneeweiss A,Barrios CH,Iwata H,Diéras V,Henschel V,Molinero L,Chui SY,Maiya V,Husain A,Winer EP,Loi S,Emens LA, Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. 2020 Jan;
[PubMed PMID: 31786121]
Level 1 (high-level) evidence
[7]
Finn RS,Qin S,Ikeda M,Galle PR,Ducreux M,Kim TY,Kudo M,Breder V,Merle P,Kaseb AO,Li D,Verret W,Xu DZ,Hernandez S,Liu J,Huang C,Mulla S,Wang Y,Lim HY,Zhu AX,Cheng AL,IMbrave150 Investigators., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England journal of medicine. 2020 May 14
[PubMed PMID: 32402160]
Level 2 (mid-level) evidence
[8]
Gutzmer R,Stroyakovskiy D,Gogas H,Robert C,Lewis K,Protsenko S,Pereira RP,Eigentler T,Rutkowski P,Demidov L,Manikhas GM,Yan Y,Huang KC,Uyei A,McNally V,McArthur GA,Ascierto PA, Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF{sup}V600{/sup} mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2020 Jun 13;
[PubMed PMID: 32534646]
Level 1 (high-level) evidence
[9]
Herbst RS,Soria JC,Kowanetz M,Fine GD,Hamid O,Gordon MS,Sosman JA,McDermott DF,Powderly JD,Gettinger SN,Kohrt HE,Horn L,Lawrence DP,Rost S,Leabman M,Xiao Y,Mokatrin A,Koeppen H,Hegde PS,Mellman I,Chen DS,Hodi FS, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;
[PubMed PMID: 25428504]
[10]
Chen DS,Irving BA,Hodi FS, Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;
[PubMed PMID: 23087408]
[11]
Hoffner B,Leighl NB,Davies M, Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Cancer treatment reviews. 2020 Apr
[PubMed PMID: 32078962]
[12]
Reddy HG,Schneider BJ,Tai AW, Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. Clinical and translational gastroenterology. 2018 Sep 19
[PubMed PMID: 30228268]
[13]
Haanen JBAG,Carbonnel F,Robert C,Kerr KM,Peters S,Larkin J,Jordan K,ESMO Guidelines Committee., Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jul 1
[PubMed PMID: 28881921]
Level 1 (high-level) evidence
[14]
Suzman DL,Agrawal S,Ning YM,Maher VE,Fernandes LL,Karuri S,Tang S,Sridhara R,Schroeder J,Goldberg KB,Ibrahim A,McKee AE,Pazdur R,Beaver JA, FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. The oncologist. 2019 Apr;
[PubMed PMID: 30541754]
[15]
Schmalz O,Jacob C,Ammann J,Liss B,Iivanainen S,Kammermann M,Koivunen J,Klein A,Popescu RA, Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients. Journal of medical Internet research. 2020 Dec 21;
[PubMed PMID: 33346738]
Level 2 (mid-level) evidence